AI has become both a cultural and technical force de jour but relies inherently on the persistence of and access to data. Healthcare (HC) data is inherently fragmented and unevenly accessible due to various legislation and privacy concerns. There are also differences between HIPAA in the U.S., primarily designed for protecting patients’ data while sharing them with payers. In Europe, GDPR is primarily designed to protect individuals' fundamental rights to privacy and control over their personal data. This impacts data ownership and secondary use rights resulting in different access to healthcare and new medications. The speaker will discuss these differences and how, relative to the HC data access, artificial intelligence (AI) can be applied in different scenarios from clinical trial enablement to real-world evidence (RWE) generation as well as Health Economics and Outcomes Research as well as epidemiological studies.

The presentation will be followed by Q & A.